Protocol Ledger

Therapeutic Cohort IMM · ClinicalTrials.gov API v2

Immunology, Rheumatology, and Dermatology: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 3,376 interventional Phase II and Phase III Immunology, Rheumatology, and Dermatology protocols registered from 2018 through 2026, including 1,326 active studies, 1,249 completed studies, and 466 early-stopped studies (13.80% overall; 27.17% of closed trials).

Median Enrollment: 119.0 participants Median Completed Span: 690 days California Share: 1,099 studies (32.6%)

1. Reconciled Immunology, Rheumatology, and Dermatology Execution & Stop-Cause Profile

Immunology, Rheumatology, and Dermatology Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 3,376 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 1,326 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 1,249 / 466 27.17% closed-trial attrition ratio across 1,715 closed protocols
Slow Accrual vs Safety & Futility Stops 65 / 70 / 45 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 78.5% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Immunology, Rheumatology, and Dermatology

Consolidated Biopharma, Academic & Federal Sponsors (Immunology, Rheumatology, and Dermatology Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
AbbVie Biopharma Industry 324 128 150 189
Amgen Biopharma Industry 153 66 56 44
Incyte Biopharma Industry 119 38 47 6
UCB Biopharma Industry 86 22 49 30
Keymed Biosciences Co Biopharma Industry 49 23 17 0
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Academic / Institutional Sponsor 46 4 19 0
Sunshine Guojian Pharmaceutical (Shanghai) Co Biopharma Industry 39 14 10 0
LEO Pharma Biopharma Industry 33 5 25 0
Guangdong Hengrui Pharmaceutical Co Biopharma Industry 32 24 7 0
Charite University, Berlin, Germany Academic / Institutional Sponsor 28 9 6 0
Viatris Biopharma Industry 24 8 14 61
Celltrion Biopharma Industry 23 5 16 12

3. Representative Multi-Center Phase II & III Immunology, Rheumatology, and Dermatology Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Immunology, Rheumatology, and Dermatology
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07453004 A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis TJ Biopharma Co Phase II RECRUITING
NCT07378527 Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria Beijing InnoCare Pharma Tech Co Phase II/III RECRUITING
NCT07515014 A Study of E6742 in Participants With Systemic Lupus Erythematosus Eisai Phase II RECRUITING
NCT07184944 A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Sanofi Phase III RECRUITING
NCT07265570 Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) InSilico Medicine Hong Kong Limited Phase II RECRUITING
NCT06842199 Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis Beijing InnoCare Pharma Tech Co Phase III RECRUITING
NCT07440537 Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study Beijing InnoCare Pharma Tech Co Phase II RECRUITING
NCT07185009 A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Sanofi Phase III RECRUITING
NCT07047612 ICP-332 in Subjects With Non-segmental Vitiligo Beijing InnoCare Pharma Tech Co Phase II/III RECRUITING
NCT06300320 A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease Chia Tai Tianqing Pharmaceutical Group Co Phase II RECRUITING
NCT06454357 A Clinical Study of B007 in the Treatment of Pemphigus. Shanghai Jiaolian Drug Research and Development Co Phase II/III RECRUITING
NCT06775860 ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis Beijing InnoCare Pharma Tech Co Phase III RECRUITING
NCT07038382 A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis Shanghai Henlius Biotech Phase II RECRUITING
NCT07724366 A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co Phase III RECRUITING
NCT07184996 An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Sanofi Phase III RECRUITING
NCT07184931 An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Sanofi Phase III RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI